Blue Star Q2 FY27: PAT +25% YoY but Flat Ex-Exceptional as RAC Margins Stay Squeezed
PAT +25.44% YoY · revenue +21% · margins compressing
₹2,930.95 Cr
+21% YoY
₹123.91 Cr
+25.44% YoY
4.2%
+0.1pp YoY
₹6.03
Blue Star's consolidated PAT rose 25.4% YoY to ₹123.91 Cr on revenue up 21.0% YoY to ₹2,930.95 Cr, but the headline is flattered by a ₹23.02 Cr exceptional gain from the sale of its Medtech business. Strip that out and PBT-before-exceptional items grew just 1.6% YoY (₹134.28 Cr vs ₹132.17 Cr), with adjusted PAT growth around +2% — essentially flat earnings power despite strong topline growth. No formal street consensus specific to this quarter could be located (results were filed same-day); a web search found no Q2 FY27-specific brokerage preview, so vsStreet is unknown rather than assumed.
Q2 FY-2027 vs prior quarters
The margin story is the quarter: consolidated OPM compressed to 6.91% from 7.57% a year ago, and the squeeze is concentrated in the Unitary (room-AC) segment, whose EBIT margin was just 2.31% in Q2 (2.72% for H1) — far below the >6.5% FY27 guidance (aspiring 7-7.5%) management set on last quarter's call. The Electro-mechanical/commercial-AC segment, by contrast, held margin at 6.88% in Q2 (6.83% H1), squarely within its guided 6.5-7% band, so the miss is guidance-specific to RAC, not company-wide. This confirms rather than surprises: management had already been publicly warning that an 8% price hike effective October 1, 2026 would still be insufficient to offset a cumulative ~18% rise in copper, steel and logistics costs since January 2026, with only a fraction of planned hikes passed through due to a delayed summer and competitor pricing pressure.
The stock went into the print at ₹1,673, up 6.2% over the past month of trading.
For context: this is the second-highest quarterly PAT of the last 6 quarters.
What the summary numbers don't show
₹23.02 Cr exceptional gain from sale of Medtech business by subsidiary Blue Star Engineering & Electronics; H1 exceptional total ₹32.19 Cr also includes a ₹9.17 Cr property-sale gain booked in Q1
FY27 Segment II EBIT margin >6.5% (aspires 7-7.5%); Segment I 6.5-7%. Data center MEP: ₹3,000 Cr order inflow, ₹1,400 Cr revenue FY27; ₹4,000 Crore revenue by FY29. RAC market 18% CAGR potential over 5-year period.
— This quarter: missed
Segment revenue mix shows where growth came from: Unitary products revenue grew 29.4% YoY to ₹897.66 Cr even as its margin collapsed, while Electro-mechanical/commercial-AC grew 16.3% YoY to ₹1,935.99 Cr at a steady margin. The 13.2% QoQ revenue decline (₹3,377.92 Cr to ₹2,930.95 Cr) is pure AC seasonality — Unitary revenue fell 46.9% QoQ as the summer selling season rolled off — not a demand signal. Standalone PAT of ₹38.24 Cr (vs consolidated ₹123.91 Cr) reflects that the Medtech exceptional gain and most overseas-subsidiary contribution sit outside the standalone entity. Separately, Blue Star's Oman arbitration saw WJT's claims dismissed (Sep 15, 2026) — a legal overhang cleared, though not a P&L item this quarter. The filing carries no fresh disclosure on the data-center MEP pipeline (₹3,000 Cr order inflow / ₹1,400 Cr revenue FY27 targets flagged last quarter), so that guidance remains unverified this print.
W1
FY27 Segment II (Unitary/RAC) EBIT margin guided >6.5% (aspiring 7-7.5%) vs just 2.72% in H1 — watch whether the 8% price hike effective Oct 1, 2026 closes the gap in H2
W2
Management flagged input costs (copper, steel, logistics) up ~18% cumulatively since Jan 2026 with price hikes only partially passed through — watch Q3 commentary on whether the latest hike holds against competitor pricing
W3
Data-center MEP pipeline (₹3,000 Cr order inflow, ₹1,400 Cr revenue FY27 target; ₹4,000 Cr revenue by FY29) was not disclosed in this filing — watch for an update next quarter
Consolidated PBT includes a ₹23.02 Cr exceptional gain (Medtech business sale by subsidiary Blue Star Engineering & Electronics); H1 exceptional total ₹32.19 Cr also folds in a ₹9.17 Cr property-sale gain booked in Q1, which sits in the standalone books. NCI of ₹(0.01) Cr makes period profit (123.91) marginally differ from owners'-attributable profit (123.92). All figures legible, limited-review report unmodified.
Informational and educational content only. Not investment advice.